536748-06-8

Upstream product

• 536748-05-7 3-fluoro-N,N-dimethyl-4-nitrobenzamide 
• 157665-51-5 3-fluoro-4-nitrobenzoyl chloride 
• 455-87-8 4-amino-3-fluorobenzoic acid 
• 506-59-2 N,N-dimethylammonium chloride 
• 403-21-4 3-fluoro-4-nitrobenzoic acid 

Downstream Products

• 1236281-72-3 tert-butyl 4-[4-(4-dimethylcarbamoyl-2-fluorophenylamino)-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl]piperidine-1-carboxylate 
• 1369872-11-6 1-(6-(4-(dimethylcarbamoyl)-2-fluorophenylamino)-5-fluoropyrimidin-4-yl)piperidine-4-carboxylic acid 
• 1369872-12-7 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-N,N-dimethylbenzamide 
• 1370016-94-6 (E)-1-(6-(4-(dimethylcarbamoyl)-2-fluorophenylamino)-5-fluoropyrimidin-4-yl)-N-(2-fluoro-1-(hydroxyimino)-2-methylpropyl)piperidine-4-carboxamide 
• 1369872-08-1 ethyl 1-(6-(4-(dimethylcarbamoyl)-2-fluorophenylamino)-5-fluoropyrimidin-4-yl)piperidine-4-carboxylate 

Relevant academic research and scientific papers

SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: (Formula AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to the GPR119 receptor agonists:3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-N,N-dimethylbenzamide; -fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadia

NOVEL PYRROLOY2,3-d¨PYRIMIDINE COMPOUND

Disclosed is a novel pyrrolo[2,3-d]pyrimidine compound represented by formula [I] or a pharmacologically acceptable salt thereof, which has a GPR119 receptor agonistic activity and is useful for a pharmaceutical. In formula [I], E represents a group repre

Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade

The present invention provides compounds of Formula (I): wherein A, B, C, G, and W1 have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful to treat thrombotic disorders. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, processes for preparing compounds of Formula I, and intermediates useful for preparing compounds of Formula I.